Narcolepsy with resolution of cataplexy and persisting orexin deficiency.


Journal

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
ISSN: 1550-9397
Titre abrégé: J Clin Sleep Med
Pays: United States
ID NLM: 101231977

Informations de publication

Date de publication:
15 08 2020
Historique:
pubmed: 15 5 2020
medline: 24 6 2021
entrez: 15 5 2020
Statut: ppublish

Résumé

Narcolepsy type 1 is a debilitating chronic neurological disorder, whose main symptoms of excessive daytime sleepiness and cataplexy may partially improve with time, but typically do not fully resolve. The irreversible loss of orexin neurons is considered to be the pivotal mechanistic link underlying the development of cataplectic attacks in narcolepsy type 1. Here we describe a case of untreated narcolepsy type 1with low cerebrospinal orexin levels (< 50 pg/mL), where cataplexy fully resolved in the first 5-6 years after disease onset, whereas excessive daytime sleepiness persisted.

Identifiants

pubmed: 32406370
doi: 10.5664/jcsm.8572
pmc: PMC7446074
doi:

Substances chimiques

Orexins 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

1383-1386

Informations de copyright

© 2020 American Academy of Sleep Medicine.

Références

Am J Psychiatry. 2010 Aug;167(8):925-33
pubmed: 20439388
Brain. 2013 Dec;136(Pt 12):3787-95
pubmed: 24142146
Nat Commun. 2017 Mar 22;8:14611
pubmed: 28327612
Nat Rev Neurol. 2019 Sep;15(9):519-539
pubmed: 31324898
Can J Neurol Sci. 1983 May;10(2):100-4
pubmed: 6861006
J Clin Sleep Med. 2016 Mar;12(3):449-50
pubmed: 26564387
Front Genet. 2019 Jun 14;10:523
pubmed: 31258545
Mol Psychiatry. 2013 Nov;18(11):1147
pubmed: 24153054
Sci Transl Med. 2018 Jun 27;10(447):
pubmed: 29950444
Med Sci (Basel). 2019 Nov 27;7(12):
pubmed: 31783668
Behav Brain Funct. 2018 Dec 26;14(1):19
pubmed: 30587203
Sleep Med. 2008 May;9(4):425-33
pubmed: 17681883
Nat Sci Sleep. 2019 Oct 21;11:231-239
pubmed: 31695532
Sleep. 2017 Jan 01;40(1):
pubmed: 28364477
Psychiatry Clin Neurosci. 2001 Jun;55(3):241-2
pubmed: 11422857

Auteurs

Danielle Wasserman (D)

Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, United Kingdom.
Sleep Disorders Centre, Guy's and St, Thomas' National Health Service Foundation Trust, London, United Kingdom.

Claudio L A Bassetti (CLA)

Department of Neurology, Inselspital, University of Bern, Switzerland.
Neurology Department, Sechenov First Moscow State Medical University, Moscow, Russia.

Ivana Rosenzweig (I)

Sleep and Brain Plasticity Centre, Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, United Kingdom.
Sleep Disorders Centre, Guy's and St, Thomas' National Health Service Foundation Trust, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH